Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
Healthcare
$4.07 +1.13%
+$0.05 today
- Market cap
- $623.90M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
52W Low $3.04High $5.10
Volume 2.44M
Average 1.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$39.64M
FY 2025 · Annual
Investing Cash Flow
$15.58M
FY 2025 · Annual
-32.1% YoYFinancing Cash Flow
$5.72M
FY 2025 · Annual
-89.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| Deferred Income Tax | (8.18M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Change in Working Capital | 930K | 29.24M | (18.23M) | (2.83M) | (10.02M) |
| Accounts Receivables | 413K | (453K) | (424K) | (633K) | 1.38M |
| Inventory | (1.91M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.91M | 5.22M | 0 | 0 | (2.11M) |
| Other Working Capital | 517K | 24.48M | (17.81M) | (2.2M) | (9.29M) |
| Other Non-Cash Items | 7.79M | (3.75M) | (5.56M) | (2.47M) | (3.43M) |
| Operating Cash Flow | (67.53M) | (35.36M) | (85.94M) | (64.85M) | (39.64M) |
| Capital Expenditures | (809K) | (512K) | (1.01M) | (182K) | 0 |
| Acquisitions (Net) | 1.81M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.22M) | (130.43M) | (80.51M) | (141.51M) | 12.87M |
| Sales of Investments | 70.35M | 56M | 132.27M | 164.64M | 155.28M |
| Other Investing Activities | (1.81M) | 0 | 20K | 0 | (152.56M) |
| Investing Cash Flow | (12.68M) | (74.94M) | 50.77M | 22.95M | 15.58M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 134.67M | 20.32M | 29.85M | 44.12M | 5.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (12.14M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14.71M | 11.49M | 795K | 7.87M | 0 |
| Financing Cash Flow | 137.24M | 31.81M | 30.65M | 52M | 5.72M |
| Effect of Forex Changes | 5K | (22K) | 25K | (49K) | 14K |
| Net Change in Cash | 57.03M | (78.51M) | (4.49M) | 10.05M | (18.32M) |
| Free Cash Flow | (68.34M) | (35.87M) | (86.94M) | (65.03M) | (39.64M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$33.5M
+ D&A$363.0K
+ Stock-Based Comp$7.0M
+ Deferred Tax$0
- Working Capital-$10.0M
- Other Non-Cash-$3.4M
= Operating Cash Flow-$39.6M
- Capex$0
= Free Cash Flow-$39.6M
Analysis
FY2025 free cash flow is -$39.6M. FCF conversion is 118.3% of net income. Operating cash flow was -$39.6M, with capex of $0. The largest bridge item is Working Capital at -$10.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 8-K | Current report | Oct 22, 2026 |
Does ABUS generate free cash flow?
Arbutus Biopharma Corporation (ABUS) generated -$39.64M of free cash flow in fiscal 2025.
How much operating cash flow does ABUS produce?
Operating cash flow was -$39.64M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.